The pharmaceutical landscape for respiratory health faced a significant setback this week as GSK announced the discontinuation of its clinical development program for camlipixant, a drug once hailed as a potential blockbuster for the treatment of refractory chronic cough (RCC). The decision follows an analysis of mixed data from two pivotal Phase 3 clinical trials, CALM-1 and CALM-2, which failed to demonstrate a level of efficacy sufficient to transform the current standard of care. This move marks a sharp turn for a program that GSK acquired just over a year ago in a multi-billion dollar deal, highlighting the inherent risks and clinical complexities of targeting the neurological pathways associated with chronic coughing.
Refractory chronic cough is defined as a persistent cough lasting more than eight weeks that remains unresolved despite optimal treatment for underlying conditions or for which no identifiable cause can be found. It is a condition that affects millions of individuals globally, often leading to physical exhaustion, social embarrassment, and a significantly diminished quality of life. Despite the prevalence of the condition, there are currently no treatments approved by the U.S. Food and Drug Administration (FDA) specifically for RCC, leaving a massive void in the respiratory therapeutic market.
The CALM Trial Results and Statistical Shortfalls
The termination of camlipixant’s development in RCC stems from the top-line results of the CALM-1 and CALM-2 trials. These were global, randomized, double-blind, placebo-controlled Phase 3 studies designed to evaluate the safety and efficacy of camlipixant over 12 and 24 weeks, respectively. The trials tested two different doses—a low dose and a high dose—of the oral, twice-daily pill against a placebo arm.
According to the data provided by GSK, the trials yielded inconsistent outcomes. In the CALM-1 study, the high-dose cohort achieved the primary endpoint, demonstrating a statistically significant reduction in 24-hour cough frequency at the 12-week mark when compared to the placebo. However, this success was not replicated in the CALM-2 study, where the high dose failed to reach statistical significance for the primary endpoint at week 24. Furthermore, the low-dose arm of the drug failed to meet the primary endpoint in either of the two studies.
Beyond the primary metrics, GSK reported that camlipixant did not achieve the necessary thresholds for key secondary endpoints in either trial. These secondary measures typically include patient-reported outcomes, such as the Cough Quality of Life Questionnaire (CQLQ) and the Visual Analogue Scale (VAS) for cough severity. The inability to show a consistent, dose-dependent improvement across both trials led GSK’s leadership to conclude that the drug’s clinical profile was insufficient to warrant further investment for this specific indication.
A $2 Billion Strategic Setback
The failure of camlipixant is particularly notable due to the financial weight of its acquisition. In April 2023, GSK reached an agreement to acquire Bellus Health, a Canadian biotechnology firm based in Laval, Quebec, for approximately $2 billion. The centerpiece of the acquisition was camlipixant, which was then entering its final stages of clinical testing.
At the time of the deal, GSK was optimistic about the drug’s potential to dominate the RCC market. The acquisition was seen as a strategic move to bolster GSK’s respiratory pipeline, a traditional stronghold for the company. GSK executives pointed to the Phase 2b SOOTHE trial data, which had shown that camlipixant significantly reduced cough frequency with a favorable safety profile. The market for chronic cough treatments was estimated to be worth billions, and GSK anticipated a regulatory filing and launch that would place them at the forefront of the field.
With the discontinuation of the RCC program, GSK faces a significant write-down on the value of the Bellus acquisition. While the company maintains that its disciplined approach to R&D necessitates stopping programs that do not meet high efficacy bars, the loss of a late-stage asset is a blow to its near-term growth projections in the respiratory sector.
The Science of P2X3 Antagonism
Camlipixant belongs to a class of drugs known as P2X3 receptor antagonists. The P2X3 receptor is an ATP-gated ion channel found on the peripheral sensory nerve fibers, specifically the C-fibers in the airways. In patients with chronic cough, these receptors are believed to become hypersensitized, leading to an exaggerated cough reflex in response to minor irritants or even normal breathing.
By blocking the P2X3 receptor, camlipixant aimed to dampen this hypersensitivity and reduce the urge to cough. The challenge for researchers in this class has been "selectivity." Another receptor in the same family, P2X2/3, is involved in the sense of taste. Early P2X3 inhibitors often caused a side effect known as dysgeusia, or a persistent bitter or metallic taste, because they inadvertently blocked the receptors on the tongue.
Camlipixant was engineered to be highly selective for the P2X3 receptor over the P2X2/3 receptor, with the goal of providing relief from coughing without the burdensome taste disturbances that plagued earlier candidates. While GSK’s recent update noted that camlipixant’s safety profile was similar to the placebo—suggesting that the selectivity goal may have been reached—the lack of robust efficacy rendered the safety benefits secondary.
Lessons from the Regulatory History of Chronic Cough
GSK’s struggle with camlipixant mirrors the difficulties faced by other pharmaceutical giants in the RCC space. Merck & Co. has long been the leader in the P2X3 field with its candidate, gefapixant (marketed as Lyfnua in some regions). While gefapixant has received regulatory approval in Japan and the European Union, it has faced repeated setbacks in the United States.
In early 2022 and again in late 2023, the FDA issued Complete Response Letters (CRLs) to Merck regarding gefapixant. The federal agency did not raise concerns about the drug’s safety but rather questioned whether the "modest" reduction in cough frequency observed in trials was clinically meaningful for patients. The FDA’s high bar for efficacy in chronic cough has become a significant hurdle for the entire class of P2X3 inhibitors.
The failure of camlipixant further suggests that targeting the peripheral P2X3 pathway may not be a sufficient "one-size-fits-all" solution for the complex neurology of chronic cough. It raises questions about whether the biological mechanism of cough hypersensitivity is more diverse than previously thought, requiring perhaps a multi-targeted or centrally acting approach rather than a peripheral one.
A Pivot to Irritable Bowel Syndrome
Despite the termination of the RCC program, camlipixant’s journey within GSK’s pipeline is not entirely over. The company confirmed that it will continue to explore the drug’s potential in other therapeutic areas where P2X3 receptors play a role.
GSK is currently conducting a Phase 2b clinical trial evaluating camlipixant for the treatment of Irritable Bowel Syndrome (IBS). Specifically, the study focuses on patients with diarrhea-predominant IBS (IBS-D) and mixed-type IBS (IBS-M). In these conditions, P2X3 receptors in the gastrointestinal tract are thought to contribute to visceral hypersensitivity and abdominal pain.
Because the Phase 3 CALM trials demonstrated that camlipixant is generally well-tolerated and has a safety profile comparable to a placebo, GSK believes there is still a viable path forward for the molecule in treating chronic pain and discomfort associated with IBS. The ongoing Phase 2b trial will be a critical "proof-of-concept" for whether the P2X3 mechanism is better suited for enteric applications than respiratory ones.
The Competitive Shift: Trevi Therapeutics and Haduvio
The exit of GSK from the chronic cough market has immediate implications for the remaining competitors. Most notably, Trevi Therapeutics stands to gain from the reduced competition. Trevi is developing Haduvio (an oral extended-release formulation of nalbuphine) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and for refractory chronic cough.
Unlike the P2X3 antagonists, Haduvio utilizes a centrally acting mechanism. It targets both the kappa-opioid receptors (which inhibit cough) and the mu-opioid receptors (which can modulate pain and itch). Analysts, including Roanna Ruiz of Leerink Partners, have noted that the failure of camlipixant reinforces the difficulty of the peripheral approach and may validate Trevi’s strategy of targeting the central nervous system’s cough centers.
With GSK and Merck facing significant hurdles, Trevi’s Haduvio is now positioned as a potential frontrunner, provided it can navigate its own upcoming Phase 3 trials successfully. The shift in the landscape suggests that the next generation of cough therapies may move away from the P2X3 class entirely if more consistent data does not emerge.
Impact on the Patient Community
For the millions of patients suffering from refractory chronic cough, the news of camlipixant’s failure is a disheartening development. Many patients with RCC have spent years cycling through off-label treatments, such as gabapentin, amitriptyline, or inhaled corticosteroids, often with little relief and significant side effects.
The clinical trial failures underscore the need for more sophisticated diagnostic tools to categorize cough phenotypes. Medical experts suggest that chronic cough may be a collection of different endotypes, meaning that while the symptom (coughing) is the same, the underlying biological drivers differ from patient to patient. Until researchers can better identify which patients will respond to peripheral versus central inhibitors, the "trial and error" nature of cough treatment is likely to persist.
Conclusion and Future Outlook
GSK’s decision to halt camlipixant’s development for refractory chronic cough serves as a stark reminder of the "valley of death" in drug development, where even $2 billion assets can falter in the face of Phase 3 complexity. While the financial impact on GSK is notable, the company’s pivot toward IBS testing indicates a desire to salvage value from the Bellus acquisition.
The broader pharmaceutical industry will likely view this event as a signal to reassess the P2X3 pathway’s viability for respiratory indications. As the focus shifts toward central-acting mechanisms and alternative pathways, the search for a definitive cure for chronic cough remains one of the most challenging frontiers in modern pulmonology. For now, the medical community remains in a holding pattern, waiting for a breakthrough that can finally provide relief to those silenced by the persistence of an unbreakable cough.
